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Abstract: Many researchers have claimed they have found a successful inhibitor of Hsp90; however, we suspect they are only 
successful when the inhibitor is used in large quantities. On top of being one of the easiest ways to show an effective inhibitor, 
researchers are claiming they have found an inhibitor when only meeting as few as two hallmarks. Due to the researchers’ inhibitors 
only meeting two of the criteria, we are trying to show whether these limited expectations are a valid way in identifying Hsp90 
inhibitors. We think the client depletion assay test is not specific to Hsp90 inhibitors but instead is a generalized cell response to cell 
death. At this point in our research, we know a lot about client depletion assays and Hsp90s; however, we do not know if the claims 
these researchers are making are valid claims because of the amount of Hsp90 inhibitor they are using. 
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Introduction 
Heat shock protein 90 (Hsp90s), being one of 
the most abundant heat shock proteins (Neckers 2002), 
target individual proteins that have folded onto 
themselves incorrectly. They work to unfold these 
proteins and refold them the correct way. If the protein 
continues to fold incorrectly, the cell could go into a 
state of programmed cell death - apoptosis. The cell 
will eventually go into apoptosis if enough proteins are 
folded incorrectly or if enough other things go wrong 
within the cell. The process of apoptosis is highly 
regulated in the body, because it is hard to stop once 
the process has begun. Because Hsp90s monitor the 
folding of proteins and help to make sure the proteins 
are in order, Hsp90s are called molecular chaperones. 
Hsp90s have been researched for many years because 
they are more sensitive in cancer cells. Cancer cells 
require more Hsp90 than normal cells to survive, 
suggesting that they play a huge role in the growth of 
cancer tumors (Tsutsumi et al. 2009). Hsp90s help 
enhance telomerase, which causes cancer progression 
(Neckers 2002).  
Inhibitors, or compounds found to restrict the 
number of Hsp90s’ functions, work by competing with 
ATP binding, causing the chaperone cycle to slow or 
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completely stop. This process decreases the amount of 
client proteins able to be unfolded, eventually causing 
more cells to go into apoptosis (Tsutsumi et al. 2009). 
Hsp90s’ client proteins play a big role in the 
establishment of cancer and the hallmarks, or changes, 
they make to the cell that helps them to continuously 
keep growing. Some of these hallmarks include: self-
sufficient growth signals, the abilities to avoid signals 
from other proteins, stop apoptosis, replicate, and 
invade tissues.  In a client depletion assay, the 
experimenter administers a candidate inhibitor to see 
whether it stops Hsp90 from functioning in the cell. 
The inhibitors indirectly target proteins that Hsp90 
unfold, and the inhibitors cut the Hsp90 off from 
helping the protein. The protein not being able to fold 
correctly causes the client protein to slowly destabilize 
and eventually degrade (Neckers 2002). In our 
experiment, we were working with paclitaxel, a 
chemotherapy drug, which is proven to not be an 
Hsp90 inhibitor. As discussed, Hsp90 inhibitors cause 
client depletion because they slow the process of 
correcting proteins folded incorrectly. This causes 
more cells to go into apoptosis.  However, if paclitaxel 




depletion is not specific to Hsp90 inhibitors and is 
rather a generalized cell response. 
Methods 
In our lab, we did our testing on Jurkat cells, a 
type of leukemia cell line. We grew 25 milliliters of 
the cancer cells for each drug concentration we used in 
a 25 milliliter flask. This was done by making cell 
cultures. In our research, we did suspension cultures - 
when the cells are free floating in Roswell Park 
Memorial Institute media, which contains fetal bovine 
serum (Pierce 89986) 200 mM L-glutamine, 500 
nM/ml streptomycin, and 100 U/ml penicillin 
(Voruganti et. al). Once the media and cells were 
mixed, they were cultured overnight statically in a 
humidified CO2 incubator at 37℃ (Voruganti et. al). 
After incubating overnight, we put paclitaxel, a 
chemotherapy drug, into one of the flasks. We did a 
drug dose curve by a multiple of 10 nM increments, so 
we could measure if the client depletion assay 
decreased, stayed the same, or increased, further 
showing if it was a Hsp90 inhibitor or not.  
We compared the cultures’ client depletion 
assays using a Western blot test (Figure 1). After the 
gel was ran, the membrane of the gel was taken and 
put into an antibody that was specific to our protein. 
Then, another antibody that had an enzyme attached 
was added to the membrane to induce staining, 
radioactivity, etc. The membrane was then put into a 
substrate which made the antibody with the enzyme 
glow, helping us to be able to identify the protein by 
observing the proteins the antibody latches onto. The 
Western Blot test we used was the SuperSignal West 
Pico PLUS Chemiluminescent Substrate. We were 
also able to tell by the color intensity of the band on 
the gel and were also able to estimate the size of the 
protein. 
We also performed another test to compare the 
samples net protein concentration called the BCA 
assay - an abbreviation for bicinchoninic acid assay. 
We compared the colors of the net proteins after 
inserting the BCA compound (Figure 2). The BCA 
compound is green before binding to the proteins. 
After binding, the compound turns purple. We were 
able to determine the concentration of protein by 
visually comparing the color intensity of each sample. 
The more protein there are in the lysate, the darker the 
solution will look. We used a plate reader to obtain a 
specific concentration of proteins within each of our 
samples. 
Figure 1: These are the results from our 
Western blot. Based off of these results as 
well as results from previous experiments, 
we were able to conclude Hsp90s are not a 
cause of cell apoptosis. Photo courtesy of 
SuperSignal West Pico PLUS 
Chemiluminescent Substrate. 
Figure 2: This figure is the results of our BCA 
assay. Visually, we were able to tell which samples 
had more protein concentration based off the darker 




Results and Discussion 
In conclusion, our lab still has quite a few 
questions we want answered. Our Hsp70 did not 
induce; therefore, it is probably not an Hsp90 
inhibitor. Also, there was no evidence for the dose 
dependent depletion of CDK1 or hnRNP, meaning it 
is most likely not an Hsp90 inhibitor. In our 
experiment, there was also an error in line loading. 
There was also an error in our PARP, which leaves us 
with a lot of questions about dose efficiency. 
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